Interleukin 15 - Admune Therapeutics

Drug Profile

Interleukin 15 - Admune Therapeutics

Alternative Names: Heterodimeric IL-15; Heterodimeric Interleukin 15; hetIL-15; IL 15; NIZ985; sIL 15Ra

Latest Information Update: 30 Oct 2015

Price : $50

At a glance

  • Originator Admune Therapeutics
  • Developer Admune Therapeutics; National Cancer Institute (USA)
  • Class Adjuvants; Interleukins
  • Mechanism of Action Immunomodulators; Interleukin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 21 Oct 2015 Admune Therapeutics has been acquired by Novartis
  • 05 Jun 2015 Interleukin 15 - Admune Therapeutics is available for licensing as of 05 Jun 2015.
  • 01 Jun 2015 Phase-I clinical trials in Solid tumours (Second-line therapy or greater, Metastatic disease, Late-stage disease) in USA (SC) (NCT02452268)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top